FDA approval for Casgevy (from Catapult’s regulatory round-up – December 2023)
FDA has granted BLA approval for Casgevy for the treatment of sickle cell disease (SCD) in patients 12 years of age or older with recurrent vaso-occlusive crises (VOCs). Casgevy is the first FDA-approved therapy utilizing CRISPR/Cas9, a type of genome editing technology. Patients’ hematopoietic (blood) stem cells are modified by genome editing using CRISPR/Cas9 technology.
Published on the 5th of January 2024. Read the entire regulatory round-up for December 2023 here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (7 août 2024). FDA approval for Casgevy (from Catapult’s regulatory round-up – December 2023). ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/1258k





